文献速递冠心病血脂与心血管预防

心肌梗死后使用非甾体抗炎药的心血管与出血风险

Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该韩国全国队列研究纳入108,232例首次诊断心肌梗死患者,评估抗血栓药物组及NSAID亚型对心血管和出血事件风险的影响。结果显示,合用NSAID显著增加心血管事件(HR 6.96)和出血事件(HR 4.08)风险;在NSAID亚型中,塞来昔布和美洛昔康的风险最低。

要点

  • 心肌梗死后合用NSAID显著增加心血管事件和出血事件风险。
  • 塞来昔布和美洛昔康在NSAID亚型中心血管及出血风险最低。
  • 心肌梗死后应避免使用NSAID,若无法避免可考虑塞来昔布或美洛昔康。

核心结论

  • 心肌梗死后合用NSAID显著增加心血管事件和出血事件风险。
  • 尽管心肌梗死后应避免NSAID,但在无法避免的情况下,塞来昔布和美洛昔康可考虑作为替代选择。

研究设计与样本

  • 基于韩国健康保险审查评估服务数据库的全国队列研究,纳入2009至2013年首次诊断心肌梗死的108,232例患者。
  • 患者根据处方抗血栓药物分组,评估持续NSAID治疗及NSAID亚型对不良临床事件风险的影响。

主要发现

  • 与未使用NSAID相比,合用NSAID显著增加心血管事件风险(HR 6.96;95%CI 6.24-6.77;p<0.001)。
  • 与未使用NSAID相比,合用NSAID显著增加出血事件风险(HR 4.08;95%CI 3.51-4.73;p<0.001)。
  • 在NSAID亚型中,塞来昔布的心血管事件风险HR为4.65(95%CI 3.17-6.82;p<0.001),出血事件风险HR为3.44(95%CI 2.20-5.39;p<0.001)。
  • 美洛昔康的心血管事件风险HR为3.03(95%CI 1.68-5.47;p<0.001),出血事件风险HR为2.80(95%CI 1.40-5.60;p<0.001)。

临床怎么用

  • 心肌梗死后应避免使用NSAID。
  • 若NSAID使用不可避免,可考虑塞来昔布或美洛昔康作为替代选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data are available regarding the risk for adverse clinical events with concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment after myocardial infarction (MI). OBJECTIVES: The aim of this study was to investigate the risk for cardiovascular and bleeding events according to groups of antithrombotic medications and subtypes of NSAIDs in patients with MI. METHODS: This was a nationwide cohort study to enroll a study population from the Health Insurance Review and Assessment Service database in Korea between 2009 and 2013. Patients were divided into groups on the basis of the prescribed antithrombotic medications. The primary and secondary outcomes were thromboembolic cardiovascular and clinically relevant bleeding events. The risk for adverse clinical events was assessed by ongoing NSAID treatment and subtypes of NSAIDs. RESULTS: In total, 108,232 patients (mean age 64.2 ± 12.8 years, 72.1% men, mean follow-up duration 2.3 ± 1.8 years) with first diagnosed MI were enrolled. Concomitant NSAID treatment significantly increased the risk for cardiovascular events (hazard ratio [HR]: 6.96; 95% confidence interval [CI]: 6.24 to 6.77; p < 0.001) and bleeding events (HR: 4.08; 95% CI: 3.51 to 4.73; p < 0.001) compared with no NSAID treatment. Among NSAID subtypes, the risk for cardiovascular and bleeding events was lowest with the use of celecoxib (HR: 4.65; 95% CI: 3.17 to 6.82; p < 0.001, and 3.44; 95% CI: 2.20 to 5.39; p < 0.001, respectively) and meloxicam (HR: 3.03; 95% CI: 1.68 to 5.47; p < 0.001, and 2.80; 95% CI: 1.40 to 5.60; p < 0.001, respectively). CONCLUSIONS: Concomitant NSAID treatment significantly increased the risk for cardiovascular and bleeding events after MI. Although NSAID treatment should be avoided after MI, celecoxib and meloxicam could be considered as alternative options in cases in which NSAID use is unavoidable.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kang DO, An H, Park GU, et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020. PMID: 32731930. doi:10.1016/j.jacc.2020.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。